FDA Panel Votes to Yank Preterm Birth Drug Off Market

October 19, 2022 by Dan McCue
FDA Panel Votes to Yank Preterm Birth Drug Off Market
(Photo by 🇸🇮 Janko Ferlič via UnSplash)

WASHINGTON — An advisory panel to the Food and Drug Administration voted Wednesday to recommend that a drug intended to prevent women from having preterm births be removed from the market.

Makena, manufactured by Covis Pharma, is the only approved treatment to reduce the risk of recurrent preterm birth in women who have a history of spontaneous preterm birth. 

Because this patient population literally had no other treatment to turn to, the FDA granted Makena accelerated approval in 2011 based on positive findings from a placebo-controlled trial with 463 participants.

But concerns about the treatment’s effectiveness lingered, and in 2019, the FDA’s Obstetrics, Reproductive and Urologic Drugs Advisory Committee voted 9-7 to withdraw Makena’s approval after confirmatory trials failed to show it was any more effective than a placebo.

Covis Pharma appealed and asked that a hearing be scheduled to allow it to fight for the treatment’s future.

In doing so, Covis CEO Michael Porter said, “We stand ready to work collaboratively with the agency to address methods of more fully understanding and maintaining this important treatment option for this high-risk, underrepresented, principally minority patient population. 

“Preterm birth is an increasing health issue in the U.S., with preterm birth rates significantly higher than in other developed countries. We believe that a thorough review of the benefits of Makena, particularly among at-risk, disadvantaged communities, is required,” Porter said.

That hearing began on Monday and concluded Wednesday. Over the past two-and-a-half days, the committee heard arguments for and against the drug, and ultimately agreed there is no reason for the drug to remain on the market if there is no evidence that shows that it is effective.

In a 14-1 vote, the panel said the drug should be yanked from the market while a confirmatory study on the drug is designed and conducted.

A spokeswoman for the FDA told The Well News via email that everything the agency has to share about the Makena Hearing will be added to the docket on Regulations.gov.

Asked what will happen next, Shannon Hatch, a spokeswoman for the agency, said, “Within 45 days after the transcript of the hearing becomes available and is posted to the docket, the presiding officer plans to issue and post a report reflecting the recommendations of the advisory committee and her own views based on the presentations at the hearing. 

“The Center for Drug Evaluation and Research and the sponsor will then have 45 days to comment on the report. FDA’s commissioner and chief scientist will review those submissions and the rest of the administrative record in making their decision for the agency and plan to do so expeditiously,” Hatch said.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • Makena
  • preterm birth
  • In The News

    Health

    Voting

    Health

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    March 26, 2024
    by Dan McCue
    Consumers Warned to Avoid Certain Topical Pain Relief Products 

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed... Read More

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed for topical use before, during or after certain cosmetic procedures. The warning came after the agency issued warning letters to six companies for marketing these products... Read More

    News From The Well
    scroll top